Open AccessS205: ZANUBRUTINIB + OBINUTUZUMAB (ZO) VS OBINUTUZUMAB (O) MONOTHERAPY IN PATIENTS (PTS) WITH RELAPSED OR REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL): PRIMARY ANALYSIS OF THE PHASE 2 RANDOMIZED ROSEWOOD TRIAL
Author(s) -
Zinzani P. L.,
Mayer J.,
Auer R.,
Bijou F.,
Oliveira A. C.,
Flowers C. R.,
Merli M.,
Bouabdallah K.,
Ganly P. S.,
Song Y.,
Zhang H.,
Johnson R.,
GarcíaSancho A. M,
Provencio M.,
Trněný M.,
Yuen S.,
Tilly H.,
Kingsley E.,
Tuyman G.,
Assouline S. E.,
Ivanova E.,
Kim P.,
Huang J.,
Delarue R.,
Trotman J.
Publication year - 2022
Publication title -
hemasphere
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 11
ISSN - 2572-9241
DOI - 10.1097/01.hs9.0000843712.33707.fe
Subject(s) - medicine , clinical endpoint , obinutuzumab , gastroenterology , phases of clinical research , follicular lymphoma , progression free survival , refractory (planetary science) , randomized controlled trial , surrogate endpoint , surgery , oncology , clinical trial , lymphoma , chemotherapy , cd20 , physics , astrobiology